2025-10-23T15:25:29-05:00 2024-12-31 580692043 MAULDIN & JENKINS LLC 200 GALLERIA PKWY SE STE 1700 ATLANTA GA 303395946 990 2024-01-01 822120760 ODYLIA THERAPEUTICS INC ODYL 4044802994 830 GLENWOOD AVE SE 510-323 ATLANTA GA 30316 ASHLEY WINSLOW CEO/CSO 4044802994 2025-10-21 1 1 MELISSA SEWARD P02145103 7709558600 2025-10-21 2024 2025-03-06 01:10:19Z ASHLEY WINSLOW 830 GLENWOOD AVE SE 510-323 ATLANTA GA 30316 482047 0 X WWW.ODYLIA.ORG X 2017 DE ODLYIA UTILIZES A UNIQUE, NON-PROFIT MODEL TO ACCELERATE THE DEVELOPMENT OF GENE THERAPIES FOR PEOPLE WITH RARE DISEASE, CHANGING THE WAY TREATMENTS ARE BROUGHT FROM THE LAB TO THE CLINIC. 6 6 4 6 0 0 289283 291256 241089 144417 40401 46374 0 0 570773 482047 0 0 0 0 537882 556221 0 0 122185 329354 143184 867236 699405 -296463 -217358 9688644 1594795 41336 907239 9647308 687556 X ODLYIA'S MISSION IS TO FACILITATE THE RESEARCH OF GENETICS, GENETIC THERAPIES AND SAFE AND EFFECTIVE TREATMENTS THAT ADDRESS RARE AND ULTRA-ARE DISEASES, INCLUDING TO (I) RESEARCH AND DEVELOP METHODOLOGIES FOR MORE EFFECTIVE AND EFFICIENT DEVELOPMENT OF THERAPIES AND TREATMENTS OF RARE AND ULTRA-RARE DISEASES INCLUDING, BUT NOT LIMITED TO, THE CONDUCT AND OVERSIGHT OF CLINICAL TRIALS, (II) COMPILE AND DISSEMINATE SCIENTIFIC LITERATURE THAT PROMOTES AND ATTRACTS RESOURCES FOR RESEARCH AND THE DEVELOPMENT OF THERAPIES AND TREATMENTS THAT ADDRESS RARE AND ULTRA-RARE DISEASES, (III) DEVELOP BEST PRACTICES IN THE FIELD OF RESEARCH AND THE DEVELOPMENT OF TREATMENTS OF RARE AND ULTRA-RARE DISEASES AND (IV) ENGAGE IN AND CARRY ON ANY SUCH OTHER ACTIVITIES IN FURTHERANCE OF SUCH PURPOSES AS NONPROFIT CORPORATIONS ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW MAY CONDUCT, BUT ONLY TO THE EXTENT THAT SUCH ACTIVITIES SHALL BE PERMITTED UNDER SECTION 50L(C)(3) OF THE CODE. 0 0 451026 144417 ADVANCING DRUG DEVELOPMENT FOR RARE DISEASES. ODYLIA'S TWO PRIMARY INITIATIVES ARE BRYDGE SOLUTIONS AND THE ODYLIA PIPELINE WHICH INCLUDES PROJECTS FOR RPGRIP1, USH1C AND NPHP1. 451026 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 0 1 4 1 0 0 0 0 0 0 0 0 0 0 0 0 X 6 6 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 0 0 MA X X THE ORGANIZATION 4044802994 830 GLENWOOD AVE SE 510-323 ATLANTA GA 30316 ASHLEY WINSLOW CEO/CSO 40.00 X 217891 0 7329 JENNIFER KLEIN MGR. OF OPERATIONS & PROG. MGMT. 40.00 X 116261 0 0 SCOTT DORFMAN BOARD CHAIR 3.00 X X 0 0 0 ELIZABETH ATTIAS BOARD MEMBER 1.00 X 0 0 0 KHANDAN BARADARAN BOARD MEMBER 1.00 X 0 0 0 BRIAN FENTON BOARD MEMBER 1.00 X 0 0 0 MATTHEW PLETCHER BOARD MEMBER 1.00 X 0 0 0 GREG ROBINSON BOARD MEMBER 1.00 X 0 0 0 334152 0 7329 2 0 1 0 0 291256 291256 SERVICE FEE REVENUE 900099 144417 144417 144417 46374 46374 482047 144417 0 46374 225221 158240 55607 11374 261918 179303 21309 61306 8338 5778 1316 1244 26735 18525 4221 3989 34009 23835 5195 4979 14593 14593 69443 65103 2231 2109 28041 4794 23247 10125 9937 188 9389 2878 6511 3848 3848 7745 242 265 7238 699405 451026 126194 122185 108152 236414 64034 673208 14000 10154 3515 0 748943 675019 8750000 0 9688644 1594795 41336 55532 851707 41336 907239 X 9647308 687556 9647308 687556 9688644 1594795 X -217358 7606 -8750000 0 X X 0 1 X 1 0 X 14111 233084 976484 289283 291256 1804218 14111 233084 976484 289283 291256 1804218 888593 915625 18882 10396 14556 40401 46374 130609 225 225 1935052 620177 0.47320 0.44010 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2020 AMOUNT: $ 225. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 597394 7606 107741 115347 482047 0 482047 807146 107741 107741 699405 0 699405 PART X, LINE 2: THE ORGANIZATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION AS DESCRIBED IN INTERNAL REVENUE CODE SECTION 501(C)(3) AND HAS BEEN CLASSIFIED BY THE INTERNAL REVENUE SERVICE AS A PUBLICLY SUPPORTED ORGANIZATION AND NOT AS A PRIVATE ORGANIZATION. HOWEVER, INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO THE ORGANIZATION'S TAX-EXEMPT PURPOSE IS SUBJECT TO TAXATION AS UNRELATED BUSINESS INCOME. THE ORGANIZATION FOLLOWS THE STATUTORY REQUIREMENTS FOR ITS INCOME TAX ACCOUNTING AND GENERALLY AVOIDS RISKS ASSOCIATED WITH POTENTIALLY PROBLEMATIC TAX POSITIONS THAT MAY BE CHALLENGED UPON EXAMINATION. MANAGEMENT BELIEVES ANY LIABILITY RESULTING FROM TAXING AUTHORITIES IMPOSING ADDITIONAL INCOME TAXES FROM ACTIVITIES DEEMED TO BE UNRELATED TO THE ORGANIZATION'S TAX-EXEMPT STATUS WOULD NOT HAVE A MATERIAL EFFECT ON THE ORGANIZATION'S FINANCIAL STATEMENTS. THE ORGANIZATION HAS NO UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740). X 0 0 0 0 0 0 0 0 0 ASHLEY WINSLOW CEO/CSO 217891 0 0 0 0 0 0 0 7329 0 225220 0 0 0 FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS TWO STATUTORY MEMBERS, THE MASSACHUSETTS EYE AND EAR INFIRMARY AND USHER 2020 FOUNDATION, INC. FORM 990, PART VI, SECTION A, LINE 7A THE ORGANIZATION'S MEMBERS CAN ELECT OR APPOINT 2 DIRECTORS OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS ARE PROVIDED WITH FORM 990 FOR THE OPPORTUNITY TO PROVIDE COMMENTS AND QUESTIONS, WITHIN TWO WEEKS OF DOCUMENT PROVISION, TO ENSURE THERE IS TIME FOR DISCUSSION BEFORE SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS AND STAFF ARE ASKED TO DISCLOSE CONFLICT OF INTEREST THROUGH A FORM THAT IS FILLED OUT. ANY CHANGES IN CONFLICT OF INTERESTS ARE ASKED TO BE UPDATED WHEN CHANGES OCCUR, AND AT LEAST ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15A DISCUSSED WITH INDUSTRY EXPERTS AND INDEPENDENT BOARD MEMBERS TO DETERMINE COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS ARE AVAILABLE UPON REQUEST. PART XII, LINE 2C THE OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. FORM 990, PART XI, LINE 8 THE STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS HAS BEEN RESTATED TO CORRECT FOR THE WRITE-OFF OF THE VALUATION OF OLD DONATED LICENSES. THE ORGANIZATION PREVIOUSLY RECOGNIZED LICENSES TO INTELLECTUAL PROPERTY AS ASSETS ON ITS STATEMENT OF FINANCIAL POSITION. UPON FURTHER REVIEW AND RE-EVALUATION OF THE UNDERLYING VALUATION METHODOLOGIES AND THE PRACTICAL UTILITY OF THESE LICENSES, IT WAS DETERMINED THAT THESE LICENSES HAD NO MEASURABLE FAIR VALUE SUBSEQUENT TO THE DONATION BUT BEFORE THE PRIOR YEAR. CONSEQUENTLY, THE PREVIOUSLY RECORDED ASSET VALUE AND CORRESPONDING CONTRIBUTION REVENUE HAVE BEEN REVERSED TO REFLECT A MORE ACCURATE FINANCIAL POSITION. CORRECTING THIS ERROR DECREASED DONATED LICENSES AND DECREASED NET ASSETS WITHOUT DONOR RESTRICTIONS BY $8,750,000 AT DECEMBER 31, 2024.